Cover Image

Discovery of Potent EGFR Inhibitors With 6-Arylureido-4-anilinoquinazoline Derivatives

According to the classical pharmacophore fusion strategy, a series of 6-arylureido-4-anilinoquinazoline derivatives (Compounds 7a-t) were designed, synthesized, and biologically evaluated by the standard CCK-8 method and enzyme inhibition assay. Among the title compounds, Compounds 7a, 7c, 7d, 7f, 7...

Full description

Saved in:

Bibliographic Details
Main Authors:	Meng Li (Author), Na Xue (Author), Xingang Liu (Author), Qiaoyun Wang (Author), Hongyi Yan (Author), Yifan Liu (Author), Lei Wang (Author), Xiaowei Shi (Author), Deying Cao (Author), Kai Zhang (Author), Yang Zhang (Author)
Format:	Book
Published:	Frontiers Media S.A., 2021-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Discovery of potent allosteric antibodies inhibiting EGFR
by: Léxane Fournier, et al.
Published: (2024)

Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor
by: Pengxing He, et al.
Published: (2019)

6,7-Disubstituted-4-anilinoquinazoline: Design, Synthesis and Anticancer Activity as a Novel Series of Potent Anticancer Agents
by: Fatemeh Azmian Moghadam, et al.
Published: (2021)

Discovery of potent histone deacetylase inhibitors with modified phenanthridine caps
by: Wenli Fan, et al.
Published: (2021)

Discovery of Quercetin and Its Analogs as Potent OXA-48 Beta-Lactamase Inhibitors
by: Yuejuan Zhang, et al.
Published: (2022)

Discovery of novel and potent CDK8 inhibitors for the treatment of acute myeloid leukaemia
by: Zhuoying Chen, et al.
Published: (2024)

A rapid and convenient method for synthesis of anilinoquinazoline: an improved synthesis of erlotinib derivatives
by: Zahra Haghighijoo, et al.
Published: (2015)

A rapid and convenient method for synthesis of anilinoquinazoline: an improved synthesis of erlotinib derivatives
by: Zahra Haghighijoo, et al.
Published: (2015)

Docking study, synthesis and antimicrobial evaluation of some novel 4-anilinoquinazoline derivatives
by: Rezvan Rezaee Nasab, et al.
Published: (2017)

A rapid and convenient method for synthesis of anilinoquinazoline: an improved synthesis of erlotinib derivatives
by: Zahra Haghighijoo, et al.
Published: (2015)

Discovery of indole-3-butyric acid derivatives as potent histone deacetylase inhibitors
by: Yiming Chen, et al.
Published: (2021)

Discovery of Potent Dual EGFR/HER2 Inhibitors Based on Thiophene Scaffold Targeting H1299 Lung Cancer Cell Line
by: Ranza Elrayess, et al.
Published: (2020)

Discovery of triterpenoids as potent dual inhibitors of pancreatic lipase and human carboxylesterase 1
by: Jing Zhang, et al.
Published: (2022)

Discovery of a potent olaparib-chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
by: Hongyu Qin, et al.
Published: (2023)

Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent
by: Liu W, et al.
Published: (2015)

Discovery of aminopyridine-containing spiro derivatives as EGFR mutations inhibitors
by: Lianbao Ye, et al.
Published: (2019)

NAD(P)H:quinone oxidoreductase 1 inducer activity of some novel anilinoquinazoline derivatives
by: Ghorab MM, et al.
Published: (2016)

Development of novel anilinoquinazoline-based carboxylic acids as non-classical carbonic anhydrase IX and XII inhibitors
by: Zainab M. Elsayed, et al.
Published: (2023)

Database-Guided Discovery of Potent Peptides to Combat HIV-1 or Superbugs
by: Guangshun Wang
Published: (2013)

Discovery and Identification of Pyrazolopyramidine Analogs as Novel Potent Androgen Receptor Antagonists
by: Lingyan Wang, et al.
Published: (2018)

Discovery of secondary sulphonamides as IDO1 inhibitors with potent antitumour effects in vivo
by: Shushan Ge, et al.
Published: (2020)

Structure-based drug discovery of novel fused-pyrazolone carboxamide derivatives as potent and selective AXL inhibitors
by: Feifei Fang, et al.
Published: (2023)

Editorial: Discovery of EGFR tyrosine kinase inhibitors for cancer treatment
by: Panupong Mahalapbutr, et al.
Published: (2024)

Discovery of novel coumarin derivatives as potent and orally bioavailable BRD4 inhibitors based on scaffold hopping
by: Zhimin Zhang, et al.
Published: (2019)

Discovery of TK-642 as a highly potent, selective, orally bioavailable pyrazolopyrazine-based allosteric SHP2 inhibitor
by: Kai Tang, et al.
Published: (2024)

Discovery of a Novel Nav1.7 Inhibitor From Cyriopagopus albostriatus Venom With Potent Analgesic Efficacy
by: Yunxiao Zhang, et al.
Published: (2018)

Discovery of a potent and highly selective inhibitor of SIRT6 against pancreatic cancer metastasis in vivo
by: Xinyuan Xu, et al.
Published: (2024)

Structure-guided discovery of potent and oral soluble epoxide hydrolase inhibitors for the treatment of neuropathic pain
by: Fangyu Du, et al.
Published: (2022)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
by: Zhe Zhang, et al.
Published: (2019)

Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer
by: Si-Yang Maggie Liu, et al.
Published: (2023)

Discovery of potent and noncovalent KRASG12D inhibitors: Structure-based virtual screening and biological evaluation
by: Yuting Wang, et al.
Published: (2022)

Discovery of a Novel, Selective and Irreversible Inhibitor (Abivertinib) of Mutated EGFR and T790M-induced Resistance for the Treatment of NSCLC
by: Long Mao, et al.
Published: (2020)

Discovery of N-(2-Aminophenyl)-4-(bis(2-chloroethyl)amino)Benzamide as a Potent Histone Deacetylase Inhibitor
by: Lihui Zhang, et al.
Published: (2019)

Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1
by: Mingxing Hu, et al.
Published: (2020)

Discovery of novel thiosemicarbazone derivatives with potent and selective anti-Candida glabrata activity
by: Xianru Li, et al.
Published: (2023)

Discovery of LAH-1 as potent c-Met inhibitor for the treatment of non-small cell lung cancer
by: Lijie Sima, et al.
Published: (2024)

EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
by: Chenguang Li, et al.
Published: (2018)

The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in EGFR-Mutant NSCLC
by: Wang Z, et al.
Published: (2022)

Discovery and characterization of novel potent non-covalent small molecule inhibitors targeting papain-like protease from SARS-CoV-2
by: Miao Zheng, et al.
Published: (2024)

A high expression EGFR/cell membrane chromatography and online high performance liquid chromatography/mass spectrometry method for screening EGFR antagonists from Rhizoma Polygoni Cuspidati
by: Meng Sun, et al.
Published: (2011)